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Kay Friedrichs* and Martin H CarstensenAbstract
Background: Scalp cooling is a long known method to reduce chemotherapy-induced alopecia in cancer patients
with solid tumors. Due to a progress in this method, a medical device enabling individual feedback-controlled
temperature regulation was evaluated.
Between June 2011 and December 2012, 83 breast cancer patients were included. Evaluation was focussed on the
quantification of alopecia, satisfaction and side effects of the scalp cooling system in (neo-) adjuvant chemotherapy
regimens. Alopecia quantification was done by patient evaluation and experts rating.
Findings: Based on patient hair loss evaluations, the mean overall success rate of scalp cooling (<50% hair loss) in
(neo-) adjuvant chemotherapy was at 52.6%. 51.7% of patients in (neo-) adjuvant CT did not need head covers. In
51.7% of patients in (neo-) adjuvant chemotherapy hair regrowth occurred. Patient satisfaction rate was between
VAS 70 and 80 (0–100, where 100 is completely satisfied).
Conclusion: The evaluation demonstrates that feedback-controlled scalp cooling provides a good chance for breast
cancer patients to keep their hair even during (neo-)adjuvant chemotherapies, which are known to cause severe to
complete alopecia without scalp cooling.
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Chemotherapy-induced alopecia (CIA) causes consider-
able impact on the quality of life of patients during cancer
treatment. CIA starts approximately within 2–4 weeks
and is complete 1–2 months after the initiation of chemo-
therapy (CT) (Batchelor 2001). Although a number of
publications recently refer to the problem of CIA (e.g.
(Komen et al. 2013; Van den Hurk et al. 2010)), scalp cool-
ing (SC) as suitable solution is often not offered to
patients.
Various SC devices exist since the 1970’s. Their efficacy,
handling and control are limited. Particularly a direct
temperature control and regulation of the scalp during
cooling procedure was not possible. Although several* Correspondence: friedrichs@mammazentrum.eu
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reproduction in any medium, provided the origpublications report the efficacy of modern systems, SC still
has the image of being ineffective (Tollenaar et al. 1994;
Middleton et al. 1985).
The DigniCap® System (Dignitana, Sweden) is a new
medical device for SC treatment during CT. The system
enables feedback-controlled regulation of SC by direct
measurement of the patient’s individual scalp temperature.
The clinical evaluation of the system was performed at
Mammazentrum Hamburg. This evaluation was fo-
cussed on the results for hair loss, patient satisfaction
and SC related side effects in breast cancer patients
treated with (neo-)adjuvant CTs.Material and methods
The evaluated SC system consists of a computer con-
trolled refrigerator unit connected through hoses to a
silicon cap in which liquid coolant circulates throughinger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Table 1 Chemotherapy regimens, dosages, post-cooling
times and number of patients who finished the DigniCap
evaluation





E90C600 (q3w*4) - > Doc100/175 (q3w*4)
1 32 100
F500E100C500 (q3w*6) 15 120
F500E100C500 (q3w*3) - > Doc100 (q3w*3) 7 120 - > 100
E90C600 (q3w*4) 3 100







1Three patients were included receiving three-weekly (neo-)adjuvant Doc/EC.
Of them, one patient was treated with Doc175 and two with Doc100.
2One patient finished an adjuvant CT (EC/Doc) before a palliative treatment
(three cycles Carboplatin followed by two cycles Gemcitabine/Cisplatin)
was started.
Table 2 Selected characteristics of the patient cohort in
the clinical evaluation
Median age
(neo-)adjuvant CT scalp cooling finished n = 58 47 years (range:
28–74 years)
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sensors in the silicone cap independently controlling scalp
temperature of the front and the back side of the head,
plus one safety sensor to ensure that the temperature does
not go below the freezing point.
The SC procedure starts at room temperature with the
fit of the silicone cap on the patients head. Patient hair
is wetted to ensure better heat conductivity. The silicone
cap is covered by an insulating neoprene cap. If follows
the pre-cooling time of usually 20 minutes were the pa-
tients scalp is continually cooled down to the pre-set
treatment temperature (3-5°C). This temperature is
sensor-controlled and kept during the following CT in-
fusion time. After the CT infusion is finished, the SC is
continued for the post-cooling time. The post-cooling
time protects the hair follicles from the peak toxicity of
the CT drugs. The duration of the post cooling time de-
pends on the CT regimen (30–150 minutes).
Between June 2011 and December 2012 a total of 83
breast cancer patients were included in the evaluation. In-
clusion criteria were: Age ≥18 years; female; signed in-
formed consent; confirmed primary or metastasized breast
cancer; normal hair distribution at baseline as judged by a
physician; ECOG performance status 0–2; assigned for CT;
capacity and willingness to comply with study procedure;
estimated life expectance must be greater than 6 months.
Exclusion criteria were: prior administration of chemother-
apy within 2 years of recruitment; prior radiotherapy treat-
ment involving the head; inherent alopecia due to other
causes; any conditions which have contraindications men-
tioned in the IFU of the evaluated system.
Table 1 shows the types of applied CTs, the correspond-
ing number of patients who finished CT and SC and the
CT-specific post-cooling times. Selected characteristics
(age, menopausal status and ethnic phenotype) of the
patient cohort are summarized in Table 2. 58 patients
received a (neo-)adjuvant chemotherapy with SC, six
patients were treated in a palliative setting. As the
number of patients in palliative treatment is relatively
low the results are not separated by CT regimen.
Anonymized patient data were gathered by completion
of questionnaires after each CT-cycle. Patients evaluated
their hair loss, their satisfaction and SC-related magni-
tude of different possible side effects on a visual analog
scale (VAS, range 0–100) in the following matter:
No hair loss - total hair loss; completely unsatisfied -
completely satisfied; no side effect – strongest possible
side effect.
Moreover patients were asked whether and when they
used a head cover. Every patient who wore a head cover
at least once during CT, was rated as head cover user.
A set of photographs was taken from each patient be-
fore each CT-cycle. After the patients faces were covered
and records were anonymized, the sets of photographswere randomized for CT-cycle and rated for hair loss
and hair regrowth by an expert from the Institute of
Cosmetic Science, Hamburg University, Dept. of Chem-
istry, Division of Biochemistry and Molecular Biology to
provide an objective rating. Rating categories were de-
fined according to a modified version of Dean’s scale for
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different scales to evaluate the extent of hair loss during
CT. Many authors refer to the WHO scale for hair loss
(World Health Organisation 1979; Massey 2004) al-
though modifications are often not indicated. As the
WHO scale has the disadvantage that hair loss cannot
be expressed quantitatively, which hampers statistical
analysis, some authors prefer Dean’s scale for hair loss
quantification (Dean et al. 1979). This scale with original
four percentage-based categories of hair loss was modi-
fied to the five categories of the WHO scale (e.g. Rugo
et al. 2013). However, Dean’s scale categories should not
be directly compared with grading criteria scales that
base on WHO (Connie et al. 2004). Table 3 shows a
comparison of hair loss scales used in scientific publica-
tions. The hair loss scale used in this evaluation (Table 3)
is a modified version of Dean’s scale (Rugo et al. 2013),
slightly changed to avoid the value overlap bias of the
original scale.
According to Rugo et al. (2013) scalp cooling is suc-
cessful with a hair loss ≤50% (Grades 0, 1 and 2) as 50%
is the threshold where hair loss becomes noticeably vis-
ible (Breed et al. 2011). Based on this categorization, the
success rate of SC in this evaluation was calculated at
the end of the CTs (patient evaluation/experts rating).
To enable comparability between expert rating and pa-
tients’ evaluations, patients VAS hair loss evaluations were
transferred to percentages and grouped in the Dean’s scale
for hair loss before data analysis.
Statistical analysis of the data was performed by medi-
stat GmbH, Kiel, Germany. Focus was set on the efficacy
of the SC system manifested in the rate of hair loss, num-
ber of patients using head cover, SC-related side effects,
regrowth of hair and the satisfaction of the patients with
the amount of preserved hair.
Results
Scalp cooling during (neo-)adjuvant chemotherapy
The overall success rate of SC during (neo-)adjuvant CT
calculated from patient evaluation and experts rating (PE
and ER) is 52.6%/53.5% (Table 4). The overall success rate
in the group with the most frequently applied CT-regime
(EC/Doc) is 46.8%/53.5%. Due to the low number of
cases in other CT-regimens, the number of patientsTable 3 Selected different classifications for hair loss evaluati
Grade 0 Grade 1 G
WHO (1979) No change Minimal hair loss M
Massey (2004) No significant hair loss Minor hair loss M
Dean (1979) 0-25% 25-50% 5
Rugo (2013) 0% <25% 2
This evaluation 0% 1-24% 2with successful SC might be more informative than per-
centages. Patients treated with EC (3 patients): 2 (PE)/1
(ER); patients treated with FEC (17 patients): 9 (PE)/9
(ER); patients treated with FEC/Doc (7 patients): 4
(PE)/2 (ER).
28/58 patients (48.3%) receiving (neo-)adjuvant CT
used head covers (Table 5) like wig, cap or scarf. 17/29
patients (58.6%) used their head cover permanently,
whereas 12/29 patients (41.4%) used a head cover some-
times, e.g. when going out.
Hair regrowth was observed on photographs in 30/58
(51.7%) patients receiving a (neo-)adjuvant CT. Major
contribution came from 26 patients treated with EC/Doc
where 20 patients were rated with hair regrowth (76.9%).
Figure 1 shows that in this subgroup hair regrowth
mainly occurred in the second half of CT. In all three
patients receiving Doc/EC included in the analysis of
this group, hair regrowth was observed under EC, i.e.
in the second part of the CT. All visible hair regrowth
was made up by regular hair and not by the often ob-
served fine and curly chemotherapy-hair (Katakunnel &
Berger 2008).
Satisfaction evaluation with respect to hair preserva-
tion and the scalp cooling treatment (Table 6) provided
comparable results with (mean/median) VAS 71/75 and
VAS 73/80 satisfaction of all patients receiving (neo-)
adjuvant CT.Scalp cooling during palliative chemotherapy
All six patients evaluated SC as successful receiving
palliative CT’s. Five patients were rated as success by
the expert (Table 4).
One patient treated with palliative chemotherapy used
a head cover (Table 5).
Patients treated with palliative CT were generally
more satisfied (Table 6) than patients in (neo-)adjuvant
CT with (mean/median) VAS 92/95 (hair preservation)
and VAS 94/100 (scalp cooling treatment).All patients
Side effects of scalp cooling were evaluated by the patients
on a VAS scale. Table 7 summarizes the side effects most
frequently rated as strong, i.e. ≥50%. Only 2 out of 19on found in the literature
rade2 Grade 3 Grade 4








Table 4 Mean hair loss at the end of CT (last rated CT-cycle) evaluated by patients (PE) and rated by expert (ER)
Threshold for successful scalp cooling is 50% (visible) hair loss, i.e. the limit between grades 2 and 3 (n (%))
Grade (hair loss) Success No success
0 1 2 3 4
(Neo-)adjuvant CT
Success rate 31 (52.6) 28 (47.5)
Σ all CT PE
Σ all CT ER 31 (53.5) 271 (46.6)
PE 1 (1.7) 7 (11.9) 23 (39.0) 19 (32.2) 9 (15.3)
ER1 3 (5.2) 12 (20.7) 16 (27.6) 19 (32.8) 8 (13.8)
Success rate 2 (66.6) 1 (33.3)
Σ all EC PE
Σ all EC ER 1 (33.3) 2 (66.6)
EC PE - 1 (33.3) 1 (33.3) - 1 (33.3)
EC ER - 1 (33.3) - 1 (33.3) 1 (33.3)
Success rate 15 (46.8) 17 (53.1)
Σ all EC/Doc PE
Σ all EC/Doc ER 17 (54.9) 14 (45.2)
EC/Doc PE 1 (3.1) 5 (15.6) 9 (28.1) 13 (40.6) 4 (12.5)
EC/Doc ER1 2 (6.5) 6 (19.4) 9 (29.0) 11 (35.5) 3 (9.7)
Success rate 9 (60.0) 6 (40.0)
Σ all FEC PE
Σ all FEC ER 9 (60.0) 6 (40.0)
FEC PE - 1 (6.7) 8 (53.3) 3 (20.0) 3 (20.0)
FEC ER 1 (6.7) 5 (33.3) 3 (20.0) 5 (33.3) 1 (6.7)
Success rate 4 (57.1) 3 (42.9)
Σ all FEC/Doc PE
Σ all FEC/Doc ER 2 (28.6) 5 (71.5)
FEC/Doc PE - - 4 (57.1) 2 (28.6) 1 (14.3)
FEC/Doc ER - - 2 (28.6) 2 (28.6) 3 (42.9)
Palliative CT
Success rate 6 (100) -
Σ all PE
Σ all ER 5 (83.4) 1 (16.7)
PE 1 (16.7) 4 (66.7) 1 (16.7) - -
ER 3 (50) 1 (16.7) 1 (16.7) 1 (16.7) -
1The African patient was not rated.
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physical side effects (one due to feeling cold and one due
to headache). The frequency of side effects was generally
higher in patients with (neo-)adjuvant CT compared to
patients in palliative CT regimens. Feeling cold was the
most frequent side effect in (neo-)adjuvant treatments
(37.9%), followed by headache (24.1%), heaviness of head
(18.9%) and scalp pain (10.3%). Patients with palliative
treatment reported feeling cold in two cases (33.3%) andscalp pain in one case (16.7%) as the most frequent side
effects.
64/83 (77%) patients finished CT and SC treatment
(Table 1). Of the 19 patients who dropped-out, nine pa-
tients (10.8%) stopped due to unspecified intolerance,
five (6.0%) patients due to hair loss, three patients
(3.6%) due to cancer related emergency cases or disease
progression and two patients (2.4%) due to SC-related
side effects (feeling cold, headache).
Table 5 Use of head cover by chemotherapy (n/%)








Palliative CT 1 -
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The success of scalp cooling and other related results (e.
g. patient satisfaction) is very much dependent on the
applied CT-regimens (Komen et al. 2013). Different
methods for the prevention of CIA are used since the
1970ies. For some SC methods, high discomfort and
weak success rates needed to be tolerated by the patients
(Breed et al. 2011). This might be the main reasons why
SC is still not broadly accepted. However, since CIA is
one of the most distressing side effects of CT, several ef-
forts for improvement of SC are done. Some crucial fac-
tors for successful SC are meanwhile identified, e.g.:
1) Optimal fit of the cooling cap, target temperature,
temperature control, device handling and logistics.
2) The type of drugs and their combinations and the
individual drug doses.
One technique for SC is based on gel caps. This re-
quires multiple caps that need to be changed several
times during treatment and a refrigerator unit for cool-
ing. The cooling has no temperature control and the op-
timal fit of the caps needs to be found after each change
of the cap and therefore causes high discomfort for the
patients. The more advanced technology of liquid cooled
caps still has the drawback of lacking temperature con-
trol. Only the system in this evaluation provides aFigure 1 Percentages of patients with hair regrowth (n = 20) in breas
shown due to specific CT-cycle.feedback-controlled temperature regulation independent
for the backside of the head and for the forehead, ensur-
ing optimal SC temperature for every individual patient
at any time.
Strong alopecia is particularly caused by anthracyclines
(e.g. epirubicin, adriamycin) (Breed et al. 2011). Even
stronger toxicity towards the hair roots is expected for
combinations of anthracyclines with taxanes, which are
belonging to the most frequently applied regiment for
treatment of primary breast cancer. Since a variety of
(neo-)adjuvant CT regimens are used in different dosages,
mixed with different contributions of palliative CT-
regimens, all these factors need to be taken into account
when comparing study results. In our study 54/58 patients
were treated according to the guidelines of AGO breast
commitee (AGO e.V) with a combination of anthracycline
(dose of 90–100 mg/m2) and taxane (dose ≥100 mg/m2).
In all cases, epirubicin was combined with cyclophospha-
mide (500 or 600 mg/m2). Mols et al. (2009) found for dif-
ferent adjuvant CT-regimens, that breast cancer patients
who did not receive SC reported average hair loss VAS 85
(range 9 to 100), where 100 is complete hair loss. This
supports the common experience that current (neo-)adju-
vant CT for breast cancer is causing complete alopecia in
almost all cases.
In our study we considered the evaluation and rating
of hair loss at the final CT-cycle as the most relevant
result of scalp cooling. The mean success rate of SC in
patients under (neo-)adjuvant CT (patient evaluation/
experts rating) was 52.6%/53.5% and for patients in pallia-
tive treatment (patient evaluation/experts rating) 100%/
83.3%. Remarkable are the very comparable results of pa-
tient evaluation and expert rating. This suggests that, al-
though under the impression of the distressing impact of
chemotherapy, patients were able to neutrally quantify
their hair loss. In the entire Dutch Scalp Cooling Registry,
with a 71% contribution of several adjuvant and even in-
cluding 29% of different palliative CT regimens known to
cause less CIA, a success rate of 50% was found based on
a non-use of wigs (Van den Hurk et al. 2012). Breed at al.t cancer patients under EC/Doc (n = 26). The observed regrowth is
Table 6 Satisfaction evaluation for hair preservation at
the end of CT (last rated CT-cycle) and with the scalp
cooling treatment in VAS (0–100)
Satisfaction with hair preservation
(Neo-) adjuvant CT mean sd median max min
all 71 25 75 100 8
EC 70 20 70 90 50
EC/Doc 71 28 80 100 8
FEC 75 20 75 100 30
FEC/Doc 57 24 60 85 15
Palliative CT 92 11 95 100 70
Satisfaction with scalp cooling treatment
(Neo-) adjuvant CT
all 73 26 80 100 1
EC 68 18 65 90 50
EC/Doc 71 28 80 100 1
FEC 82 18 80 100 20
FEC/Doc 65 25 70 100 10
Palliative CT 94 10 100 100 50
Friedrichs and Carstensen SpringerPlus 2014, 3:500 Page 6 of 7
http://www.springerplus.com/content/3/1/500(2011) published SC results in The Netherlands between
2006 and 2009 separated by CT regimens. They found a
success rate for FEC (drug doses: 500/100/500 mg/m2)
and FEC- > Doc (drug doses: 500/100/500- > 100 mg/m2)
SC success rates of 47% and 33%. In our study the success
rate of feedback controlled SC is higher with (PE/ER)
60.0%/60.0% and 57.1/28.6% in FEC and FEC/Doc CT
regimens.
Palliative CT regimens generally cause less alopecia
(Van den Hurk et al. 2012), which is also supported by
our data as all patients treated with palliative CT in this
study evaluated their scalp cooling as success. Even the
patient who was rated by the expert to no success
(Table 4) filed a satisfied evaluation (VAS 90).
In some publications the SC success rate was indirectly
calculated from head cover use (Van den Hurk et al. 2010;
Mols et al. 2009). According to our evaluation of head
cover use, 51.7% of the patients did not use any head
cover, although all of them received (neo-)adjuvant CT-
regimens in comparatively high doses.Table 7 The most important side effects rated as strong
by patients (VAS ≥50)
Side effect ≥50% Patients with adjuvant
CT (n = 58)
Patients with
palliative CT (n = 6)
Feeling cold 22 (37.9%) 2 (33,3%)
Headache 14 (24.1%) 0
Heaviness of head 11 (18.9%) 0
Scalp pain 6 (10.3%) 1 (16,7%)The frequency of wearing a head cover might be influ-
enced by culture, self-esteem, sex and mentality of the
patients. Moreover, like the success rate of SC, the head
cover rate is very much dependent on CT regime and its
dosage. For example by increasing the epirubicin dose in
the FEC-regime from 90 to 100 mg/m2, the rate of pa-
tients using a head cover increased from 33% to 52%, re-
spectively (Katakunnel & Berger 2008). Van den Hurk
et al. (2010) and Mols et al. (2009) showed that 52% of
breast cancer patients in various adjuvant CTs with SC
did not use a wig while only 2.7% of the control group
required none. In another study van den Hurk et al.
(2012) found a head cover rate of 49% with a change
from 5% (no cooling) to 49% (cooling, factor 10).
Within the group of patients receiving (neo-)adjuvant
CTs, the rate of hair regrowth in our study was at 51.7%.
It was also observed that hair regrowth mostly started in
the second half of CT, e.g. under Doc in the EC/Doc re-
gime). As hair regrowth could be observed when EC was
applied in the second half of CT, this suggests that re-
growth might be not only influenced by drug type, but
also by the time period since initiation of alopecia.
Moreover, even in cases where SC was not able to com-
pletely prevent alopecia, the observation of hair re-
growth a certain time after initial hair loss suggests that
SC has at least some protective effect on the hair folli-
cles, since hair regrowth occurred relatively early and
with normal hair quality and density.
Based on this assumption, we hypothesise that SC might
also have a prophylactic effect in prevention of permanent
CIA, which is known to occur in CT’s containing cyclo-
phosphamide, carboplatin, doxetacel and paclitaxel (Breed
et al. 2011; Prevezas et al. 2009). However, this needs fur-
ther investigation. Reports about hair regrowth during CT
are rare. Most relevant publications provide regrowth data
a couple of weeks or even months after CT. Van den Hurk
et al. (2010) found lower rates of hair regrowth during CT
of 24% studying a patients cohort with solid tumors
(mainly breast cancer) treated with different adjuvant and
palliative CT-regimens. The control group of the study
(no SC) had a rate of hair regrowth of 7%.
Our satisfaction evaluation was focussed on hair pres-
ervation and the SC treatment just after the last CT-
cycle. In summary, an average satisfaction rate between
VAS 70 and 80 was found. Van den Hurk et al. (2013)
provided data about CIA on a VAS scale and the satis-
faction with the patients’ hair style 3 weeks after finish-
ing CT. They found 85% satisfaction (SC patients) and
78% satisfaction in the control group (without SC). The
high degree of patient satisfaction also in the control
group suggests that patient satisfaction at least in this
study is not strongly dependent on CIA. Studies to fur-
ther investigate the reasons determining patient satisfac-
tion are necessary.
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(2.4%) were due to SC-specific physical side effects. 9/83
(10.8%) patients stopped due to unspecific intolerance,
which at least in some cases might be summarized as side
effects anticipated from chemotherapy. In total 77.1% of
breast cancer patients included in this study finished the
treatment. Patients were treated with heating blankets,
hot beverages or in some cases with pain killers, e.g. Ibu-
profen 400. The four most prominent SC related side ef-
fects in this evaluation (Table 7) were also the most
frequent in several other studies (Breed et al. 2011). How-
ever, due to the feedback-controlled temperature regula-
tion, the evaluated SC system provides results among the
best tolerance scores published in literature. Based on sev-
eral studies, the mean tolerance of SC was calculated to
VAS 6.9 to 8.0 (range 0–10) with 10 as “really well toler-
able” (Breed et al. 2011).
Conclusions
This evaluation of the DigniCap System demonstrated
that feedback-controlled SC provides a good chance for
breast cancer patients to keep their hair during combined
anthracycline and taxane containing (neo-)adjuvant CTs.
Even under initial hair loss, there is a reasonable chance
to get hair regrowth during continued SC and CT. SC-
related side effects are mild, the cooling treatment is well
tolerated and possibly most important, provides a high de-
gree of patient satisfaction.
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